1
|
Willems S, Tilz RR, Steven D, Kääb S, Wegscheider K, Gellér L, Meyer C, Heeger CH, Metzner A, Sinner MF, Schlüter M, Nordbeck P, Eckardt L, Bogossian H, Sultan A, Wenzel B, Kuck KH, Piorkowski C, Lebedev D, Kautzner J, Sticherling C, Deneke T, Rostock T, Ukena C, Kuniss M, Makimoto H, Hindricks G, Bänsch D, Schreieck J, Kolb C, Geller J, Pokushalov E, Gutleben K, Sommer P, Boldt L, Parwani A. Preventive or Deferred Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy and Implantable Defibrillator (BERLIN VT). Circulation 2020; 141:1057-1067. [DOI: 10.1161/circulationaha.119.043400] [Citation(s) in RCA: 62] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Catheter ablation for ventricular tachycardia (VT) reduces the recurrence of VT in patients with implantable cardioverter-defibrillators (ICDs). The appropriate timing of VT ablation and its effects on mortality and heart failure progression remain a matter of debate. In patients with life-threatening arrhythmias necessitating ICD implantation, we compared outcomes of preventive VT ablation (undertaken before ICD implantation to prevent ICD shocks for VT) and deferred ablation after 3 ICD shocks for VT.
Methods:
The BERLIN VT study (Preventive Ablation of Ventricular Tachycardia in Patients With Myocardial Infarction) was a prospective, open, parallel, randomized trial performed at 26 centers. Patients with stable ischemic cardiomyopathy, a left ventricular ejection fraction between 30% and 50%, and documented VT were randomly assigned 1:1 to a preventive or deferred ablation strategy. The primary outcome was a composite of all-cause death and unplanned hospitalization for either symptomatic ventricular arrhythmia or worsening heart failure. Secondary outcomes included sustained ventricular tachyarrhythmia and appropriate ICD therapy. We hypothesized that preventive ablation strategy would be superior to deferred ablation strategy in the intention-to-treat population.
Results:
During a mean follow-up of 396±284 days, the primary end point occurred in 25 (32.9%) of 76 patients in the preventive ablation group and 23 (27.7%) of 83 patients in the deferred ablation group (hazard ratio, 1.09 [95% CI, 0.62–1.92];
P
=0.77). On the basis of prespecified criteria for interim analyses, the study was terminated early for futility. In the preventive versus deferred ablation group, 6 versus 2 patients died (7.9% versus 2.4%;
P
=0.18), 8 versus 2 patients were admitted for worsening heart failure (10.4% versus 2.3%;
P
=0.062), and 15 versus 21 patients were hospitalized for symptomatic ventricular arrhythmia (19.5% versus 25.3%;
P
=0.27). Among secondary outcomes, the proportions of patients with sustained ventricular tachyarrhythmia (39.7% versus 48.2%;
P
=0.050) and appropriate ICD therapy (34.2% versus 47.0%;
P
=0.020) were numerically reduced in the preventive ablation group.
Conclusions:
Preventive VT ablation before ICD implantation did not reduce mortality or hospitalization for arrhythmia or worsening heart failure during 1 year of follow-up compared with the deferred ablation strategy.
Registration:
URL:
https://www.clinicaltrials.gov
; Unique identifier: NCT02501005.
Collapse
Affiliation(s)
| | - Roland Richard Tilz
- University Hospital Lübeck, Med.Klinik II, and German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany (R.R.T., C.-H.H.)
| | - Daniel Steven
- University Heart Center Cologne, Germany (D.S., A.S.)
| | - Stefan Kääb
- Department of Medicine I, University Hospital Munich, Ludwig-Maximilian’s University Munich and German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Germany (S.K., M.F.S.)
| | - Karl Wegscheider
- Institute of Medical Biometry and Epidemiology, University Medical Center Eppendorf, Hamburg, Germany (K.W.)
| | - László Gellér
- Semmelweis Medical University, Budapest, Hungary (L.G.)
| | | | - Christian-Hendrik Heeger
- University Hospital Lübeck, Med.Klinik II, and German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck, Germany (R.R.T., C.-H.H.)
| | | | - Moritz F. Sinner
- Department of Medicine I, University Hospital Munich, Ludwig-Maximilian’s University Munich and German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Germany (S.K., M.F.S.)
| | | | | | | | | | - Arian Sultan
- University Heart Center Cologne, Germany (D.S., A.S.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Lauschke J, Busch M, Haverkamp W, Bulava A, Schneider R, Andresen D, Nägele H, Israel C, Hindricks G, Bänsch D. New implantable cardiac monitor with three-lead ECG and active noise detection. Herz 2016; 42:585-592. [DOI: 10.1007/s00059-016-4492-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2016] [Revised: 09/27/2016] [Accepted: 10/04/2016] [Indexed: 01/14/2023]
|
3
|
|
4
|
Israel C, Bänsch D, Breithardt O, Butter C, Klingenheben T, Kolb C, Lemke B, Wiegand U, Nowak B. Kommentar zu den neuen ESC-Leitlinien zur Schrittmacher- und kardialen Resynchronisationstherapie. Kardiologe 2015. [DOI: 10.1007/s12181-014-0650-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
5
|
Bänsch D. [Ablation of atrial fibrillation improves prognosis--yes]. Dtsch Med Wochenschr 2014; 139:1952. [PMID: 25225866 DOI: 10.1055/s-0034-1387253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- D Bänsch
- Medizinische Klinik I - Kardiologie - Universitätsklinik Rostock
| |
Collapse
|
6
|
Schneider R, Schneider C, Bänsch D. Spontaneous left atrial reentry tachycardias : radiofrequency ablation and outcome. Herz 2013; 40:66-72. [PMID: 23907693 DOI: 10.1007/s00059-013-3905-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2013] [Accepted: 07/01/2013] [Indexed: 11/28/2022]
Abstract
AIMS Spontaneous left atrial reentry tachycardias (LART) in patients without previous cardiac surgical or catheter ablation are rare. Several therapeutic concepts of catheter ablation have been suggested: linear lesions (LL), circumferential pulmonary vein isolation (PVI), and both (LL + PVI). METHODS AND RESULTS In all, 28 consecutive symptomatic patients with 51 LARTs presented to our institution for catheter ablation. Electroanatomical mapping was performed on 25 patients. Three patients were ablated conventionally during LART; 25 patients (89.3 %) had extensive low-voltage areas in the left atrium (atrial myopathy). One of the following ablation strategies was applied: first, LL (n = 8), second, PVI + LL (n = 11), and third PVI alone (n = 9). Fourteen patients (50 %) had a recurrent arrhythmia during a mean follow-up of 12.2 ± 11.1 months. Six patients presented with a recurrent LART (21.4 %), 4 with LART and atrial fibrillation (Afib) (14.3 %), and 4 with Afib (14.3 %). The recurrence rate of any arrhythmia (LART and Afib) was 37.5 % in the LL group, 44.4 % in the PVI group, and 63.6 % in the PVI + LL group (ns); the recurrence rate of LARTs was 12.5 % in the LL group, 22.2 % in the PVI group, and 63.6 % in the PVI + LL group (p < 0.05). CONCLUSION Atrial tachyarrhythmia recurrence after ablation of spontaneous LART in mid-term is considerable. Stable LARTs are effectively treated by LL. PVI alone may be an acceptable alternative, especially in patients with unstable LARTs and Afib. However, the risk of recurrent LARTs after a more extensive strategy with PVI and LL is considerable, probably due to proarrhythmic effects of long linear lesions.
Collapse
Affiliation(s)
- R Schneider
- Heart Center Rostock, Department of Cardiology, University of Rostock, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany
| | | | | |
Collapse
|
7
|
Schmidt E, Schneider R, Lauschke J, Wendig I, Bänsch D. The HATCH and CHA2DS2-VASc scores. Herz 2013; 39:343-8. [DOI: 10.1007/s00059-013-3835-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2013] [Accepted: 04/09/2013] [Indexed: 10/26/2022]
|
8
|
Sombetzki M, Löbermann M, Bänsch D, Schmitz KP, Sternberg K, Reisinger EC. New Developments in Device-Associated Bloodstream Infections. BIOMED ENG-BIOMED TE 2013; 58 Suppl 1:/j/bmte.2013.58.issue-s1-C/bmt-2013-4054/bmt-2013-4054.xml. [DOI: 10.1515/bmt-2013-4054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Israel CW, Bänsch D, Böcker D, Butter C, Chun J, Deisenhofer I, Eckardt L, Geller JC, Hanke T, Klingenheben T, Piorkowski C, Schumacher B. [Recommendations of the Working Group of Arrhythmias of the German Society of Cardiology on the approach to patients with Riata® and Riata ST® leads (St. Jude Medical). Nucleus of the Working Group of Arrhythmias of the German Society of Cardiology]. Herzschrittmacherther Elektrophysiol 2012; 23:107-115. [PMID: 22847674 DOI: 10.1007/s00399-012-0186-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Riata® and Riata ST® implantable cardioverter defibrillator (ICD) leads (St. Jude Medical, Sylmar, CA) show an increased incidence of insulation defects, particularly "inside-out" lead fracture where inner, separately insulated cables penetrate through the surrounding silicone of the lead body. The exact incidence of Riata® lead problems is not clear and seems to range between 2-4% per year in the first 5 years after implantation according to new registry data. We recommend beyond a detailed information the following care of patients with Riata® and Riata ST® leads: 1) Activation of automatic ICD alerts, 2) remote monitoring with automatic daily alerts whenever possible, 3) monthly ICD controls in patients at high risk (pacemaker dependency, history of ventricular tachyarrhythmias) and high or moderate lead-related risk (8F, 7F single coil), 3-monthly controls in moderate patient and lead-related risk, 3 to 6-monthly controls in low patient and lead-related risk (no bradycardia, no history of ventricular tachyarrhythmia). Every ICD control should include meticulous analysis of oversensing artifacts in stored electrograms (EGMs) of sustained and non-sustained ventricular tachyarrhythmias and registration of EGMs during provocation testing (pectoral muscle activity, arm movements). If electrical abnormalities are observed, reoperation with addition of a new ICD lead is recommended; lead extraction only if indicated according to current guidelines. Fluoroscopy should only be performed if electrical abnormalities are found by an experienced electrophysiologist and a high frame rate and resolution. Management of fluoroscopic abnormalities in the absence of electrical abnormalities is not clear. Therefore, routine fluoroscopy of patients with Riata® leads without electrical abnormalities is not recommended.
Collapse
Affiliation(s)
- C W Israel
- Klinik für Innere Medizin - Kardiologie, Diabetologie & Nephrologie, Evangelisches Krankenhaus Bielefeld, Burgsteig 13, 33617, Bielefeld, Deutschland.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Akin I, Kische S, Schneider H, Liebold A, Ortak J, Bänsch D, Rehders TC, Thiele O, Schneider R, Kundt G, Krenz H, Chatterjee T, Nienaber CA, Ince H. Surface and intracardiac ECG for discriminating conduction disorders after CoreValve implantation. Clin Res Cardiol 2011; 101:357-64. [PMID: 22179507 PMCID: PMC3326231 DOI: 10.1007/s00392-011-0400-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2011] [Accepted: 12/07/2011] [Indexed: 11/30/2022]
Abstract
Background Transcatheter aortic valve implantation (TAVI) has been developed to minimize operative morbidity and mortality in high-risk symptomatic patients unfit for open surgery. With the proximity of the aortic valve annulus to the conduction system there is, however, an unknown risk of conduction disturbances necessitating monitoring and often cardiac pacing. Materials and methods We enrolled 50 consecutive patients from January 2007 to 2008 in our prospective evaluation of conduction disturbances measured by surface and intracardiac ECG recordings. Baseline parameters, procedural characteristics as well as twelve-lead surface ECG and intracardiac conduction times were revealed pre-interventionally, after TAVI and at 7-day follow-up. Results TAVI was performed successfully in all patients. During 7 days of follow-up the rate for first-degree AV block raised from 14% at baseline to 44% at day 7 (p < 0.001), while rates for type II second- and third-degree were 0 versus 8% (p < 0.001) and 0 versus 12% (p < 0.001), respectively. Similarly, the prevalence of new left bundle branch block (LBBB) rose from 2 to 54% (p < 0.001). Intracardiac measurements revealed a prolongation of both AH and HV interval from 123.7 ± 41.6 to 136.6 ± 40.5 ms (p < 0.001) and from 54.8 ± 11.7 to 71.4 ± 20.0 ms (p < 0.001), respectively. Pacemaker implantation at a mean follow-up of 4.8 ± 1.2 days was subsequently performed in 23 patients (46%) due to complete AV block (12%) and type II second-degree AV block (8%) while another 13 patients (26%) received a pacemaker for the combination of new LBBB with marked HV prolongation. The high rate of first-degree AV block was primarily driven by an increase in HV interval. Conclusion Cardiac conduction disturbances were common in the early experience with CoreValve implantation necessitating close surveillance for at least 1 week.
Collapse
Affiliation(s)
- I Akin
- Heart Center Rostock, Department of Internal Medicine I, Rostock School of Medicine, University Hospital Rostock, Rostock, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Paranskaya L, Akin I, Chatterjee T, Ritz A, Paranski P, Rehders T, Ince H, Schneider H, Nienaber CA, Bänsch D. Ventricular tachycardia and sudden death after primary PCI-reperfusion therapy: impact on primary prevention of sudden cardiac death. Herzschrittmacherther Elektrophysiol 2011; 22:243-248. [PMID: 22124800 DOI: 10.1007/s00399-011-0160-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND Current approaches to coronary artery disease (CAD) and acute myocardial infarction (MI) may not be well represented in most primary prevention trials of sudden cardiac death (SCD). METHODS The contemporary and ongoing registry of the Rostock infarction network (Drip & Ship) represents a well-defined cohort of patients subjected to percutaneous coronary intervention (PCI) for ST-elevation infarction (STEMI) and served as the database for both candidates for an ICD for primary prevention of SCD and for sudden death (SCD) or ventricular tachycardia (VT) during follow-up. RESULTS A total of 855 consecutive patients were treated with PCI for STEMI or NSTEMI in the region of Rostock (Germany) between 2001 and 2004. While all cause mortality was still 17.2%, the SCD rate was low at 1.3% during 728 ± 366 days of follow-up. Within that time 85 patients (9.9%) developed an indication for ICD therapy due to an impaired LV function (LVEF ≤ 35%) and heart failure. Univariate predictors of an ICD indication were delayed reperfusion (p = 0.001), a high creatine kinase (CK) max (p = 0.009), a persistent wide QRS complex (p = 0.001), previous cerebrovascular events (p = 0.033), and chronic renal failure (p = 0. 001). However, only 16.5% of these patients qualifying for an ICD actually received an ICD; nevertheless, the actual SCD rate was only 3.5%, while 5.4% (46 patients) suffered VTs or ventricular fibrillation (VF). The SCD/VT rate in the entire infarct population was associated with time to reperfusion (0.032), left bundle-branch block (0.002), a longer history of CAD (0.032), and VT during follow-up. CONCLUSION While mortality in patients with STEMI is still alarming even with PCI, the risk of SCD may be considerably decreased even in patients with an LVEF below 35%. With the current approach to primary prevention of sudden cardiac death, approximately 10% of postinfarction patients qualify for ICD therapy; however this may only reach a quarter of patients prone to SCD.
Collapse
Affiliation(s)
- L Paranskaya
- Heart Center Rostock, University Hospital of Rostock, Schillingallee 35, 18055, Rostock, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Israel C, Nowak B, Willems S, Bänsch D, Butter C, Doll N, Eckardt L, Geller J, Klingenheben T, Lewalter T, Schumacher B, Wolpert C. Empfehlungen zur externen Kardioversion bei Patienten mit Herzschrittmacher oder implantiertem Kardioverter/Defibrillator. Kardiologe 2011. [DOI: 10.1007/s12181-011-0372-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
13
|
Grönefeld GC, Bänsch D. [Antiarrhythmic therapy with β-receptor antagonists]. Herzschrittmacherther Elektrophysiol 2010; 21:222-227. [PMID: 21104261 DOI: 10.1007/s00399-010-0089-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2010] [Accepted: 10/13/2010] [Indexed: 05/30/2023]
Abstract
β-Blockers are an essential component of medical therapy in patients with ischemic heart disease or cardiac dysfunction of any genesis. They have an effect at the level of the sinus and the atrioventricular node, as well as on the atrial and ventricular refractory period of the myocardium. Overall, there are complicated antifibrillatory effects which are involved in the reduction of morbidity and mortality of this the therapy. According to the guidelines, it is important to uptitrate to highest tolerated dose. In patients with atrial fibrillation, antiadrenergic therapy should be the first line treatment; if well tolerated, then β-blockers alone or as a combination with an antiarrhythmic drug is preferable. Future prospective studies on the antiarrhythmic effects in this therapeutic area should include comparisons of different α - and β-selective active substances. Increasing knowledge of the differential therapy with the available active substances including intravenously applicable short-acting β-blockers, e.g., in intensive care therapy - should distinguish the different therapeutic effects.
Collapse
Affiliation(s)
- G C Grönefeld
- I. Medizinische Abteilung, Asklepios Klinik Barmbek, Rübenkamp 220, 22291, Hamburg, Deutschland.
| | | |
Collapse
|
14
|
Nowak B, Israel C, Willems S, Bänsch D, Butter C, Doll N, Eckardt L, Geller J, Klingenheben T, Lewalter T, Schumacher B, Wolpert C. Empfehlungen zum Einsatz von Elektrokautern bei Patienten mit Herzschrittmachern und implantierten Defibrillatoren. Kardiologe 2010. [DOI: 10.1007/s12181-010-0295-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
15
|
Bänsch D, Grönefeld G. [The patient with chronic heart failure]. Herzschrittmacherther Elektrophysiol 2010; 21:112-116. [PMID: 20552318 DOI: 10.1007/s00399-010-0078-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
An expansion of the indications for the implantation of defibrillators (ICD) has not occurred as such in recent years. Nevertheless, an increase in the number of implantation figures can be expected due to the aging population and an increasing recruitment of undersupplied regions in upcoming years. Although the first defibrillator was implanted over 20 years ago in Germany and that ICD therapy is considered as the medical standard in secondary and primary prophylaxis, there are still basic questions that can only be prospectively clarified: (1) when is the right point in time for ICD implantation? (2) Can predictors, especially those with a negative predictive value, be used to exclude patients from ICD therapy? (3) Should risk stratification, which documents the current risk for a single point in time during the illness like a snapshot, more strongly reflect the development over time of the risk? In this case, it is likely that a rethinking of risk stratification, in general, to risk stratification in the sense of observation would be necessary. An adjuvant therapy in the sense of ablation of ventricular tachycardia (VT) or antiarrhythmic therapy for primary prevention of frequently occurring episodes seems to be advised based on current data. However, the right point in time for a complementary intervention is still not clear.
Collapse
Affiliation(s)
- D Bänsch
- Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Rostock, Schillingallee 35, 18055, Rostock, Deutschland.
| | | |
Collapse
|
16
|
Block M, Bänsch D, Gradaus R, Jung W, Schöls W, Stellbrink C, Wichter T, Zrenner B. Curriculum „Praxis der ICD-Therapie“. Kardiologe 2008. [DOI: 10.1007/s12181-007-0034-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Weber M, Block M, Bänsch D, Castrucci M, Gradaus R, Schriever C, Breithardt G, Böcker D. Antitachycardia pacing for rapid VT during ICD charging: a method to prevent ICD shocks. Pacing Clin Electrophysiol 2001; 24:345-51. [PMID: 11310304 DOI: 10.1046/j.1460-9592.2001.00345.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In patients with ICDs, rapid VTs are usually treated with shocks. It is unknown, if antitachycardia pacing (ATP) delivered once for rapid VT during capacitor charging can avoid painful shocks without increasing the risk of syncope. In patients in whom rapid monomorphic VT (cycle length 300-220 ms) could be reproducibly induced during predischarge ICD testing, the success of cardioversion (defibrillation threshold plus 10 J) and a single ATP attempt (burst with 8 or 16 stimuli) was compared using a randomized crossover study design. Consciousness of the patients was checked by the signal from a button constantly pushed by the patient. In 20 patients (ejection fraction 0.50 +/- 0.19) rapid VTs (253 +/- 26 ms) were reproducibly induced. A single burst successfully terminated 11 (55%) of 20 rapid VTs, 6 episodes could not be terminated with a single burst pacing and 3 VTs accelerated. Rapid VTs not terminated by ATP were significantly faster than those that could be terminated (246 vs 258 ms, P = 0.026). Cardioversion (19 +/- 3 J) terminated the VTs in all cases. No patient suffered syncope during rapid VTs. A single ATP may terminate rapid VT with cycle lengths < 300 ms in 55% of patients without increasing the risk of syncope. Therefore, in rapid VTs one attempt of ATP may be suitable as an additional therapy option during ICD capacitor charging to avoid painful shocks without compromise of safety. Thus, future ICDs should implement the option of ATP during charging of capacitors.
Collapse
Affiliation(s)
- M Weber
- Department of Cardiology and Angiology and Institute for Arteriosclerosis Research, Hospital of the Westfälische Wilhelms-University, D-48129 Münster, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Bänsch D, Castrucci M, Böcker D, Breithardt G, Block M. Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators: incidence, prediction and significance. J Am Coll Cardiol 2000; 36:557-65. [PMID: 10933372 DOI: 10.1016/s0735-1097(00)00733-6] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
OBJECTIVES This retrospective study was performed to provide data on ventricular tachycardias (VT) with a cycle length longer than the initially programmed tachycardia detection interval (TDI) in patients with implantable cardioverter defibrillators (ICDs). BACKGROUND It has been clinical practice to program a safety margin of 30 to 60 ms between the slowest spontaneous or inducible VT and the TDI. METHODS Baseline characteristics of 659 consecutive patients with ICDs were prospectively; follow-up information was retrospectively collected. RESULTS During a mean follow-up of 31+/-23 months, 377 patients (57.2%) had at least one recurrent VT or ventricular fibrillation; 47 patients (7.1%) suffered 61 VTs above the TDI. The risk of a VT above the TDI ranged between 2.7% and 3.5% per year during the first four years after ICD implantation. The difference between the cycle length of the slowest VT before ICD implantation, spontaneous or induced, and the first VT above TDI was 108+/-58 ms. Fifty-four VTs (88.5%) above the TDI were associated with significant clinical symptoms (angina or palpitation 63.9%, heart failure 6.6% and syncope 8.2%). Six patients (9.8%) had to be resuscitated. Kaplan-Meyer analysis identified New York Heart Association class II or III (p = 0.021), ejection fraction < 0.40 (p = 0.027), spontaneous (p<0.001) or inducible (p<0.001) monomorphic VTs and the use of class III antiarrhythmic drugs (amiodarone, p<0.001; sotalol, p = 0.004) as risk predictors of VTs above the TDI. The risk of recurrent VTs above TDI was 11.8%, 12.5% and 26.6% during the first, second and third year after first VT above TDI, respectively. CONCLUSIONS The risk of VTs above the TDI is significantly increased in some patients, and many VTs above TDI cause significant clinical symptoms. A larger safety margin between spontaneous or inducible VTs and the TDI seems to be necessary in selected patients. This is in conflict with an increased risk of inadequate episodes and demands highly specific and sensitive detection algorithms in these patients.
Collapse
Affiliation(s)
- D Bänsch
- Department of Cardiology/Angiology and Institute for Research in Arteriosclerosis, Westfälische Wilhelms-University, Münster, Germany.
| | | | | | | | | |
Collapse
|
19
|
Bänsch D, Böcker D, Brunn J, Weber M, Breithardt G, Block M. Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators. J Am Coll Cardiol 2000; 36:566-73. [PMID: 10933373 DOI: 10.1016/s0735-1097(00)00726-9] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
OBJECTIVES This retrospective study was undertaken to provide data on occurrence, significance and therapy of ventricular tachyarrhythmia (VT) clusters (VTCs) in patients with dilated cardiomyopathy (DCM) and implantable cardioverter defibrillators (ICDs). BACKGROUND Data on the clinical significance of VTCs are lacking in patients with DCM and ICDs. METHODS Baseline characteristics of 106 consecutive patients with DCM and ICDs were prospectively collected, and chart reviews and episode data retrospectively analyzed. A VTC was defined as > or =3 sustained VTs/24 h. RESULTS During a mean follow-up of 33+/-23 months, 73 patients (68.9%) had recurrent VT or ventricular fibrillation (VF), 43 patients (40.6%) suffered only single VTs and 30 patients (28.3%) experienced 52 clusters of VTs. Actuarial survival free of VT or VF was 44.6%, 33.0% and 26.5%, and survival free of VTC was 77.3%, 72.2% and 67.1% after one, two and three years, respectively. Independent predictors of VT clusters were heart failure before ICD implantation (p = 0.033), presenting monomorphic VT (p = 0.044), EF <0.40 (p = 0.014) and inducible mVT, especially with right bundle branch block and superior axis configuration (p<0.001). Survival free of recurrent VTCs was 50.8%, 38.1% and 19.0% after one, two and three years, respectively. Once a VTC had occurred, only 56.7%, 46.4%, 30.9% and 15.5% of patients survived and were not transplanted after one, two, three and four years, respectively. Survival was even more reduced if a VTC was associated with cardiac decompensation: 65.6% and 21.9% after one and two years, respectively. CONCLUSIONS Despite antiarrhythmic intervention, clusters of VTs occur and recur frequently in patients with DCM. They signify impaired survival, especially if they are associated with cardiac decompensation, and may be a harbinger of progressive myocardial deterioration rather than a primarily arrhythmic problem. The benefit of ICD therapy may therefore be low in these patients.
Collapse
Affiliation(s)
- D Bänsch
- Department of Cardiology, St. Georg's Hospital, Hamburg, Germany.
| | | | | | | | | | | |
Collapse
|
20
|
Weber M, Böcker D, Bänsch D, Brunn J, Castrucci M, Gradaus R, Breithardt G, Block M. Efficacy and safety of the initial use of stability and onset criteria in implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 1999; 10:145-53. [PMID: 10090217 DOI: 10.1111/j.1540-8167.1999.tb00655.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Inappropriate therapies are the most frequent adverse event in patients with implantable cardioverter defibrillators (ICDs). Most ICDs offer a stability criterion to discriminate ventricular tachycardia (VT) from atrial fibrillation and an onset criterion to discriminate VT from sinus tachycardia. The efficacy and safety of these criteria, if used immediately after implantation, is unknown. METHODS AND RESULTS In a case control study, 87 patients in whom stability and onset criteria had been activated immediately after ICD implantation were matched to 87 patients in whom these criteria had not been activated. The groups were matched for known predictors of inappropriate therapies. With stability and onset criteria off, 24 patients (28%) received inappropriate therapies due to atrial fibrillation (n = 14) or sinus tachycardia (n = 11); with stability and onset on, only 11 patients (13%) were treated by the ICD due to atrial fibrillation (n = 5) or sinus tachycardia (n = 7) (log rank: P = 0.029). Five patients suffered inappropriate therapies despite the fact that onset (n = 4) or stability (n = 1) criteria were not fulfilled once tachycardias continued for a prespecified duration. Only one patient experienced a failure to detect VT due to the onset criterion; none because of stability. CONCLUSION The immediate use of stability and onset criteria after ICD implantation reduces inappropriate therapies due to atrial fibrillation and sinus tachycardia. Because of the potential for underdetection of VT, this approach should be limited to tachycardia rates hemodynamically tolerated by the patient.
Collapse
Affiliation(s)
- M Weber
- Department of Cardiology and Angiology and Institute for Arteriosclerosis Research, Hospital of the Westfälische Wilhelms-University, Münster, Germany
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Böcker D, Bänsch D, Heinecke A, Weber M, Brunn J, Hammel D, Borggrefe M, Breithardt G, Block M. Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation 1998; 98:1636-43. [PMID: 9778329 DOI: 10.1161/01.cir.98.16.1636] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Whether patients with heart failure derive a benefit from therapy with implantable cardioverter-defibrillators (ICDs) has been questioned. The purpose of this study was to investigate whether New York Heart Association (NYHA) functional class had an impact on the potential benefit from ICD therapy as assessed from data stored in the memory of ICDs. METHODS AND RESULTS Between 1989 and 1996, 603 patients (77% men; 59% with coronary artery disease and 16% with dilated cardiomyopathy; age, 57+/-13 years; ejection fraction, 44+/-18%) were treated with an ICD with extended memory function (storage of electrograms and/or RR intervals from treated episodes) in combination with endocardial lead systems. The stages of heart failure (NYHA functional class I through III) at implantation were correlated with overall mortality and the recurrence of fast ventricular tachyarrhythmias (>240 bpm) during follow-up. The potential benefit of the device was estimated as the difference between overall mortality and the hypothetical death rate had the device not been implanted. The latter was based on the recurrence of fast and, without termination by the devices, presumably fatal ventricular tachyarrhythmias. In the overall group, a significant difference between hypothetical death rate and overall mortality was observed (13.9%, 23.5%, and 26.6% at 1, 3, and 5 years, respectively) that suggested a benefit from ICD implantation. In patients in NYHA class I, the estimated benefit, which increased over time, was 15.2%, 29.2%, and 35.6% after 1, 3, and 5 years, respectively. In patients in NYHA class II or III, the estimated benefit increased until the third year (21.8% and 21.9%, respectively) and then remained constant until the fifth year (22.9% and 23.8%, respectively). Even those patients in NYHA class III with a history of decompensated heart failure benefited from ICD implantation. CONCLUSIONS Analysis of stored ECG data suggests that in patients with a history of ventricular tachycardia or ventricular fibrillation, ICD therapy may lead to a prolongation of life in NYHA classes I through III. The initial benefit is greatest in patients in NYHA class II and class III, but the estimated benefit might persist longest for patients in NYHA class I.
Collapse
Affiliation(s)
- D Böcker
- Hospital of the Westfälische Wilhelms-University of Münster, Departments of Cardiology, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Bänsch D, Chen-Haudenschild C, Dirkes-Kersting A, Schulte H, Assmann G, von Eckardstein A. Basal growth hormone levels in women are positively correlated with high-density lipoprotein cholesterol and apolipoprotein A-I independently of insulin-like growth factor 1 or insulin. Metabolism 1998; 47:339-44. [PMID: 9500574 DOI: 10.1016/s0026-0495(98)90268-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Previous studies in growth hormone (GH)-deficient or acromegalic patients yielded contradictory results on the effect of GH on lipoprotein metabolism. In a cross-sectional study, we analyzed the relationships between unstimulated GH, insulin-like growth factor 1 (IGF1), insulin, and lipoprotein metabolism in 44 non-obese young women. On univariate analysis, basal serum levels of GH correlated positively with triglycerides, high-density lipoprotein (HDL) cholesterol, apolipoprotein A-I (apoA-I) and apoA-II and negatively with lipoprotein lipase (LPL) activity. These associations remained significant on multivariate analyses that, in addition to GH, took into account the effects of insulin or C-peptide, as well as the effects of total, protein-bound, or free IGF1. In most cases, the relationships of these lipid parameters with insulin/C-peptide and IGF1 and its free or protein-bound subfractions were opposite of those with GH and not significant. Thus, GH appears to regulate the metabolism of HDL and triglycerides independently of IGF1 and insulin.
Collapse
Affiliation(s)
- D Bänsch
- Institut für Klinische Chemie und Laboratoriumsmedizin, Zentrallaboratorium, Westfälische Wilhelms-Universität Münster, Germany
| | | | | | | | | | | |
Collapse
|
23
|
Bänsch D, Brunn J, Castrucci M, Weber M, Gietzen F, Borggrefe M, Breithardt G, Block M. Syncope in patients with an implantable cardioverter-defibrillator: incidence, prediction and implications for driving restrictions. J Am Coll Cardiol 1998; 31:608-15. [PMID: 9502643 DOI: 10.1016/s0735-1097(97)00543-3] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVES This retrospective study was undertaken to provide information on occurrence, risk prediction and prevention of syncope in patients with an implantable cardioverter-defibrillator (ICD). BACKGROUND ICDs effectively terminate ventricular tachycardia and fibrillation (VT/VF). Incapacitating symptoms, such as syncope, may still occur. METHODS We performed a retrospective analysis of data from 421 patients (clinical history, outpatient chart reviews and episode data) with mean (+/-SD) follow-up of 26 +/- 18 months. RESULTS Of 421 patients, 229 (54.4%) had recurrent VT/VF, and 62 (14.7%) had syncope. The actuarial survival rate free of VT/VF was 58%, 45% and 37% and that for survival free of syncope was 90%, 85% and 81% at 12, 24 and 36 months after implantation, respectively. Once VT/VF had occurred, 76%, 68% and 62% of patients remained free of syncope during the following 12, 24 and 36 months, and 68%, 64% and 56% remained free of second syncope 12, 24 and 36 months after first syncope, respectively. In cases of syncope, the mean cycle length (CL) of VT was 251 +/- 56 ms. A low baseline left ventricular ejection fraction (LVEF), induction of fast VT (CL <300 ms) during programmed ventricular stimulation and chronic atrial fibrillation (AF) were associated with an increased risk of syncope. If the LVEF was >40%, fast VT had not been induced, and patients had no chronic AF; 96%, 92% and 92% of patients remained free of syncope after 12, 24 and 36 months, respectively. Once patients had a VT recurrence, syncope during the first VT and a high VT rate were the strongest risk predictors of future syncope. CONCLUSIONS Identification of patients with an ICD with a low and high risk of syncope seems to be feasible and might help as a guide to driving restrictions in such patients.
Collapse
Affiliation(s)
- D Bänsch
- Department of Cardiology/Angiology and Institute for Research in Arteriosclerosis, Westfälische Wilhelms-University, Münster, Germany
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Weber M, Bänsch D, Brunn J, Böcker D, Breithardt G, Block M. [Not Available]. Herzschrittmacherther Elektrophysiol 1998; 9 Suppl 1:50-52. [PMID: 19484547 DOI: 10.1007/bf03042436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Affiliation(s)
- M Weber
- Medizinische Klinik und Poliklinik, Innere Medizin C (Kardiologie und Angiologie), und Institut für Arterioskleroseforschung, Westfälische Wilhelms-Universität, Münster, Deutschland
| | | | | | | | | | | |
Collapse
|
25
|
Bänsch D, Dirkes-Kersting A, Schulte H, Assmann G, von Eckardstein A. Basal growth hormone levels are positively correlated with high-density lipoprotein cholesterol levels in women. Metabolism 1997; 46:1039-43. [PMID: 9284893 DOI: 10.1016/s0026-0495(97)90275-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Previous studies in patients with either a deficiency or an excess of growth hormone (GH) yielded contradictory results on the regulation of lipoprotein metabolism by GH. In a cross-sectional study of 563 male and 126 female participants of the Prospective Cardiovascular Münster (PROCAM) Study, we determined biometric and demographic data, serum levels of total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, apolipoprotein (apo)A-I, A-II, and B, and unstimulated GH levels. The median of basal GH levels was higher in women than in men. Moreover, 44.2% of men but only 8.7% of women had basal GH levels less than the detection limit of 0.05 microgram/L. The relationship between basal GH and lipoprotein metabolism was investigated by univariate and multivariate regression analysis of data from 315 men and 126 women with detectable basal GH levels. In men, GH correlated positively with HDL cholesterol and negatively with body mass index (BMI), age, and triglycerides. After multivariate analysis, the correlation with triglycerides remained independent of age and BMI. Among women, GH correlated positively with the use of hormonal contraception, HDL cholesterol, apoA-I, and apoA-II, and negatively with BMI, age, menopause, triglycerides, and apoB. With multivariate analysis, the positive correlations of GH with HDL cholesterol and apoA-I in women were independent of age. BMI, menopause, and oral contraception. We conclude that GH contributes to the regulation of HDL cholesterol levels. Moreover, in women the well-known effects of exogenous estrogen or estrogen loss on HDL metabolism may be partially mediated via GH.
Collapse
Affiliation(s)
- D Bänsch
- Institut für Klinische Chemie, Westfälische Wilhelms-Universität Münster, Germany
| | | | | | | | | |
Collapse
|
26
|
Brunn J, Block M, Weber M, Bänsch D, Seifert T, Castrucci M, Isbruch F, Böcker D, Breithardt G. [Results of testing defibrillator function of implanted cardioverter/defibrillators]. Z Kardiol 1997; 86:450-9. [PMID: 9324876 DOI: 10.1007/s003920050079] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Postoperative tests of implantable cardioverter defibrillators (ICDs) are routinely performed to ensure appropriate defibrillation by the device. However, efficacy and complications of this procedure are unknown. To scrutinize the currently accepted indications to test the defibrillation function of the ICD we retrospectively analyzed 844 ICD-tests in 439 ICD-systems and 409 patients. 755 ICD-tests (89.4%) were routinely performed (57% before discharge and 43% during follow-up); 58 tests (6.9%) were performed after a change of the antiarrhythmic drug regimen, 24 tests (2.9%) after a revision of a part of the ICD-system, and seven tests (0.8%) because of a suspected dysfunction of the ICD. During routine-tests six ICD-systems (0.8%) failed to defibrillate the patient. However, in all but one test abnormalities of the ICD-system had been observed before the test. After addition of antiarrhythmic drugs, three of 58 ICD-systems (5.2%) failed to defibrillate the patient during the test (amiodarone: n = 2, flecainide: n = 1). Four of seven ICD-systems (57%) tested due to a suspected dysfunction failed to defibrillate the patient. After revisions of parts of the ICD-systems, ICD-tests never revealed a failure of defibrillation. During 16 ICD-tests (1.9%) complications occurred. The most frequent complications was inappropriate shocks (n = 10; 1.2%), the most severe one (transient) neurologic symptoms (n = 4; 0.48%). Our experience demonstrates that postoperative tests of the defibrillation function of ICDs rarely reveal ICD-dysfunction. As testing is unpleasant for the patient and not free of complications, tests might be restricted to those patients in whom an ICD-dysfunction is suspected (based on clinical presentation, results of chest-x-ray, testing of sensing signal and stimulation threshold) or class I or class III antiarrhythmic drugs have been added to the antiarrhythmic drug regimen.
Collapse
Affiliation(s)
- J Brunn
- Westfälische Wilhelms-Universität Münster, Medizinische Klinik und Poliklinik, Innere Medizin C (Kardiologie und Angiologie), Münster
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Weber M, Block M, Brunn J, Bänsch D, Böcker D, Hammel D, Gietzen F, Breithardt G. [Inadequate therapies with implantable cardioverter-defibrillators--incidence, etiology, predictive factors and preventive strategies]. Z Kardiol 1996; 85:809-19. [PMID: 9064943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Patients with implantable cardioverter defibrillators (ICD) often suffer inappropriate ICD-therapies. The incidence, causes and risk factors of ICD-therapies for a rhythm other than ventricular tachyarrhythmias (VT) were determined retrospectively in 462 consecutive patients (pts). Inappropriate ICD-therapies were identified based on stored R-R intervals and/or electrograms. Eighty-two pts (18%) had inappropriate ICD-therapies. Actuarial rates for inappropriate ICD-therapies were 13%, 20%, 24% and 29% at 1, 2, 3 and 4 years after ICD-implantation, respectively. Atrial fibrillation with rapid ventricular response was the most common cause (34 pts, 39%). In 26 pts (30%), sinus tachycardia triggered inappropriate ICD-therapies, in 21 pts (24%) overseeing, mostly due to fractures and insulation failures of the leads, in three pts atrial flutter, in two pts non-sustained VT, in one pt supra-ventricular tachycardia and in another pt T-wave double sensing caused inappropriate ICD-therapies. In order to prevent recurrences of inappropriate ICD-therapies due to atrial fibrillation or sinus tachycardia, a rate stability (n = 19) or onset (n = 15) criterion was programmed, 41 pts additionally received beta-blocking agents and/or digoxin. In pts with overseeing an operative revision of lead system was performed. During further follow-up (15 +/- 13 months), 15 pts had recurrences of inappropriate ICD-therapies (eight pts due to atrial fibrillation, three due to sinus tachycardia and four due to overseeing). On multivariate analysis (Cox regression), history of atrial fibrillation, maximum heart rate during exercise and low cut-off rate for VT-detection were predictors of inappropriate ICD-therapies. Thus, inappropriate ICD-therapies are frequent, especially in the first year after implantation. Additional detection criteria, beta-blocking agents and/or digoxin prevent recurrences in most patients. In patients with a history of atrial fibrillation, high heart rate during exercise or a low cut-off rate for VT-detection, activation of additional detection criteria should be considered directly after ICD-implantation.
Collapse
Affiliation(s)
- M Weber
- Medizinische Klinik und Poliklinik, Westfälische Wilhelms-Universität Münster
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Gabriel P, Chilla R, Kiese C, Kabas M, Bänsch D. [The Göttingen audiometric speech test for children. II. Speech audiometry of the pre-school child with a monosyllabic picture-test (author's transl)]. HNO 1976; 24:399-402. [PMID: 993084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The Göttingen audiometric speech test was originally developed for testing three to four-year old children as well as retarded children. A refinement of this test supplements the original test in order to test five and six-year old children. This latter test follows the same advantages by using one-syllable nouns in combination with four different pictures. These pictures present words containing the same vowel but in contrast to the earlier test, the word list is expanded from twenty to 100 words. Standardization of the test was obtained by testing 62 five and six-year old normal children.
Collapse
|
29
|
Chilla R, Gabriel P, Kozielski P, Bänsch D, Kabas M. [The Göttingen audiometric speech test for children. I. Speech audiometry of the young and retarded child by a picture-test (author's transl)]. HNO 1976; 24:342-6. [PMID: 993079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The Göttingen audiometric speech test was developed for testing 3 to 4-years-old and retarded children. The test presents the following advantages: 1. The child is tested by one-syllable nouns. Thus more information by speech-rhythm is prevented. 2. For each word there are given four different pictures, which present words containing the same vowel, therefore a) the possibility of choice remains constant, b) the child won't be overtaxed by too many pictures, c) the possibility of understanding the test-word by hearing the vowel alone is avoided. The test was applied to 122 3 to 6-years-old children in order to get normal values.
Collapse
|